Sage Journals: Discover world-class research

Abstract

Background

Lung adenocarcinoma (LUAD) remains one of the leading causes of cancer-related deaths worldwide, with limited therapeutic efficacy despite advances in treatment. Our study investigated the role of LINC00578 and its regulatory interaction with miR-153-5p in LUAD progression.

Methods

The expression levels of LINC00578 and miR-153-5p were assessed in LUAD tissues and adjacent normal tissues using quantitative real-time polymerase chain reaction. Associations between LINC00578 expression and clinicopathological features and patient prognosis were analyzed. Luciferase reporter assays, proliferation, migration, invasion, and apoptosis analyses, were conducted in LUAD cell lines (PC-9 and H1299) following modulation of LINC00578 and miR-153-5p expression.

Results

LINC00578 was significantly upregulated in LUAD tissues compared to adjacent normal tissues, whereas miR-153-5p was markedly downregulated. High LINC00578 expression was associated with lymph node metastasis, tumor-node-metastasis stage, and poor overall survival. Functional studies revealed that silencing LINC00578 inhibited LUAD cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, LINC00578 exerted its oncogenic effects by negatively regulating miR-153-5p expression. Inhibition of miR-153-5p reversed the tumor-suppressive effects induced by LINC00578 knockdown.

Conclusion

LINC00578 functions as an oncogenic long non-coding RNA in LUAD by promoting proliferation and metastasis through suppression of miR-153-5p. LINC00578 may serve as a novel prognostic biomarker for LUAD.

Keywords

Lung adenocarcinoma LINC00578 miR-153-5p prognosis tumor progression

Introduction

Globally, lung cancer remains the most prevalent malignancy and the primary contributor to cancer mortality. In terms of incidence, it holds the second position among cancers, preceded by prostate cancer in males and breast cancer in females.¹ Lung cancer is responsible for nearly 1.8 million annual fatalities, representing roughly 18% of global cancer mortality and ranking as the deadliest form of the disease.² Pathologically, it is classified into two main subtypes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the latter comprising about 85% of diagnoses.^3,4 Lung adenocarcinoma (LUAD) is one of the most common subtypes of NSCLC, mostly originating from the bronchial mucosal epithelium, with a few originating from the mucous glands of the large bronchioles, and mainly from the mucous glands of the small bronchioles, with more than three-quarters of the patients’ foci occurring in the periphery, and rarely with cavitary formation.⁵ Lung adenocarcinomas are relatively common in nonsmokers, women, and younger patients, with the average age of patients typically between 40 and 50 years.⁶ This characteristic makes lung adenocarcinoma somewhat different from other types of lung cancer and requires individualized treatment strategies.⁷

Long non-coding RNAs (lncRNAs), which are transcribed by RNA polymerase II, play a regulatory role in numerous cellular and biological processes.⁸ Functionally, lncRNAs are involved in cell cycle regulation, modulation of cell death, influence on cell differentiation, and the regulation of immune responses, further underscoring the complexity of lncRNA-mediated biological activities.⁹ The regulatory mechanisms of lncRNAs are considered potential factors in tumor malignant transformation primarily through the modulation of oncogenes, thereby driving cancer phenotypes. A growing body of research has confirmed lncRNAs can serve as biomarkers for tumor prediction and prognostic assessment, making them promising candidates for novel diagnostic tools and therapeutic targets in cancer.^10–12

Recent studies have revealed that LINC00578, an immune-related lncRNA, is dysregulated in NSCLC.¹³ Moreover, aberrant expression and functional roles of LINC00578 have been identified in various human malignancies, including pancreatic cancer, breast cancer, and hepatocellular carcinoma (HCC).^14–16 In pancreatic cancer, LINC00578 is highly expressed and promotes malignant tumor progression; its elevated levels are associated with poor patient prognosis, suggesting its potential as a diagnostic and prognostic biomarker as well as a therapeutic target.¹⁴ Bioinformatics analyses have identified a binding site between LINC00578 and miR-153-5p. In addition, it was found that miR-153-5p was involved in the progression of colorectal, breast, and gastric cancers.^17–19 In NSCLC, miR-153-5p expression is suppressed by the lncRNA HIF1A-AS2, and its downregulation is associated with poor prognosis in patients.²⁰ Mechanistically, miR-153-5p promotes proliferation, migration, and invasion of lung cancer cells by targeting and inhibiting ROCK1 expression, thereby activating the epithelial–mesenchymal transition (EMT) signaling pathway.²¹

This investigation examines the expression characteristics and functional roles of LINC00578 and miR-153-5p in LUAD. Using comprehensive experimental approaches and mechanistic analyses, we seek to characterize their expression profiles in LUAD specimens and evaluate potential correlations with clinical–pathological parameters and patient outcomes. The ultimate goal is to assess their potential as novel prognostic biomarkers and to provide new theoretical foundations and potential therapeutic targets for targeted treatment of LUAD.

Materials and methods

Study population and follow-up

A total of 97 patients diagnosed with LUAD and treated surgically at our hospital were included in this study. All surgical specimens met the following criteria: all patients had a single primary tumor with no other antitumor therapy, and the pathology results had been reviewed by two senior pathologists and finally determined to be primary lung adenocarcinoma. The exclusion criteria for the collection of specimens were as follows: patients who had received any neoadjuvant therapy prior to surgery; patients with a history of other tumors in the past; and patients diagnosed with other immune system disorders during the treatment period. Ethical approval for this research was obtained from the Institutional Review Board of Jinling Hospital, The Affiliated Hospital of Medical School, Nanjing University. Surgical specimens, including tumor tissues and matched normal adjacent tissues, were collected intraoperatively and histologically confirmed by two certified pathologists. All specimens were rapidly frozen at −80°C for long-term preservation prior to molecular analyses. For outcome assessment, participants received systematic postoperative surveillance via scheduled clinical evaluations or telephone follow-ups over a period ranging from 3 to 60 months. Survival metrics were prospectively recorded and statistically evaluated.

Clinicopathological staging for all patients was rigorously determined according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition.²² The tumor-node-metastasis (TNM) stage is a composite indicator encompassing: the extent of the primary tumor (T stage), lymph node involvement (N stage), and distant metastasis (M stage). Tumor differentiation grade (well, moderate, poor) was assessed independently by the pathologists as a measure of histological aggressiveness, which is related to but distinct from the T stage. All staging and grading information was extracted from the final, reviewed pathology reports.

Gene expression assessment by quantitative real-time polymerase chain reaction

Total RNA was extracted from tissues and cell lines using Trizol reagent (Invitrogen, USA) per the manufacturer's protocol. The concentration and purity of RNA were measured using a NanoDrop 2000, and only samples with an OD260/280 ratio between 1.8 and 2.0 were considered to be of high quality. For LINC00578 mRNA detection, cDNA was synthesized from 1 µg of total RNA using the PrimeScript™ RT Reagent Kit with gDNA Eraser (TaKaRa, Japan) according to the manufacturer's instructions, which includes genomic DNA removal and reverse transcription with oligo(dT) and random hexamer primers. For the specific detection of mature hsa-miR-153-5p (MIMAT0026480), cDNA was synthesized using the Mir-X™ miRNA First-Strand Synthesis Kit (TaKaRa, Japan), which employs a stem-loop reverse transcription primer specific to miR-153-5p, following the kit protocol. quantitative real-time polymerase chain reaction (qRT-PCR) for both LINC00578 and miR-153-5p was performed on a CFX96 Real-Time PCR System (Bio-Rad) using SYBR^® Premix Ex Taq™ II (TaKaRa, Kusatsu, Shiga, Japan). The thermocycling conditions were: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. GAPDH and U6 snRNA were used as endogenous controls for LINC00578 and miR-153-5p, respectively. Gene expression levels were calculated using the 2^(-ΔΔCt) method. The sequences of all primers used are listed in Supplemental Table S1.²³

Cell culture and transfection

LUAD cell lines (A549, H1299, PC-9, and H2009) and the normal human bronchial epithelial (HBE) cell line were cultured in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) and 0.1% penicillin-streptomycin. Cells were transfected with miR-153-5p inhibitors to modulate miR-153-5p expression. The LINC00578-targeting siRNA (5′-GCTGTCCACATTTTCACTATCT-3′) and a negative control siRNA (5′-UUCUCCGAACGUGUCACGUTT-3′) were designed and synthesized by Sangon Biotech (Shanghai, China). Transfections were performed at room temperature using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After 48 h, the expression levels of LINC00578 and miR-153-5p were measured to evaluate transfection efficiency.

Cell counting kit-8 assay

For cell viability assessment, cultures were plated in 96-well plates (100 μL/well) and incubated for 24 h to ensure proper attachment prior to experimental treatments. Following intervention, 10 μL of cell counting kit-8 (CCK-8) reagent (Dojindo, Kumamoto, Japan) was introduced into each well, followed by a 1–4 h dark incubation period. Absorbance measurements at 450 nm were then obtained using a microplate spectrophotometer to quantify viable cells.

Transwell assay

Cell migration was assessed using Transwell chambers without Matrigel coating. After 48 h of transfection, cells were digested and resuspended in serum-free medium. Cells were incubated at 37°C in a 5% CO₂ atmosphere for 24 h. Migrated cells on the lower surface were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet for 20 min.

For the invasion assay, the upper chambers were pre-coated with 50 μL of Matrigel and incubated at 37°C for 4 h to allow solidification. The subsequent steps were identical to those used in the migration assay, except that the incubation time was extended to 36–48 h to account for the slower invasion process. Stained cells were counted in five randomly selected fields per well under a light microscope to quantify migration and invasion capacities.

Cell apoptosis assay

Apoptosis rates were determined by flow cytometric analysis of cells double-labeled with Annexin V-FITC and propidium iodide (PI). Following transfection, harvested cells underwent fixation in 3.7% paraformaldehyde (15 min, RT) and permeabilization with 0.1% Triton X-100 (5 min), then were suspended in binding buffer. Quantitative assessment of apoptotic populations was performed using a BD FACScan.

Dual-Luciferase reporter assay

The interaction between LINC00578 and miR-153-5p was predicted by bioinformatics tools (lncRNASNP2: https://guolab.wchscu.cn/lncRNASNP#!/lncrna_info?lncrna = NONHSAT093344.2). To validate this, a DNA fragment containing the wild-type (WT) predicted binding site was amplified and inserted into the pmirGLO dual-luciferase vector (Promega, Madison, WI, USA), downstream of the firefly luciferase gene. A corresponding mutant (MT) reporter construct was generated by introducing specific nucleotide substitutions within the binding site using site-directed mutagenesis. PC-9 and H1299 cells Pirlo were co-transfected with the reporter plasmid (WT or MT) and either a synthetic miR-153-5p mimic (miR-mimic, to augment cellular miR-153-5p levels), a miR-153-5p inhibitor (antagomiR, a chemically modified antisense oligonucleotide, miR-inhibitor), or a negative control (miR-NC), (all purchased from GenePharma, Suzhou, China). After 48 h, firefly and Renilla luciferase activities were measured sequentially using the Dual-Luciferase Reporter Assay System (Promega). Firefly luminescence was normalized to Renilla luminescence for each sample. The MUT reporter serves as a critical negative control to rule off-target effects and confirm the binding site specificity of miR-153-5p.

Statistical analysis

Statistical analyses were performed with SPSS 26.0 (IBM) and GraphPad Prism 7.0. Data are expressed as mean ± standard deviation. The specific sample size (n) for each experiment is provided in the corresponding figure legends. Differences between two groups were analyzed using the two-tailed Student's t-test. Comparisons among multiple groups were performed with one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Associations between LINC00578 expression and clinicopathological variables were evaluated with the Chi-square test. Survival curves were generated by the Kaplan–Meier method and compared using the log-rank test. Prognostic factors were identified by multivariate Cox proportional hazards regression analyses. The correlation between LINC00578 and miR-153-5p expression levels was determined using Pearson's correlation analysis. A P-value < 0.05 was considered statistically significant.

Results

Association between LINC00578 expression, clinicopathological features, and prognosis in LUAD patients

Data retrieved from the UALCAN database (The Cancer Genome Atlas (TCGA)-LUAD cohort) showed that LINC00578 was significantly upregulated in primary LUAD tumors compared with normal lung tissues (P = 3.94 × 10⁻²³, Figure 1(a)). Consistent with this public dataset, our detection of clinical specimens further demonstrated that LINC00578 expression was remarkably higher in LUAD tissues relative to matched adjacent normal controls (P < 0.001, Figure 1(b)). Kaplan–Meier survival analysis based on the mean expression level of LINC00578 (low, n = 46; high, n = 51) revealed that patients with higher LINC00578 expression had a significantly poorer overall survival (log-rank P = 0.012, Figure 1(c)). Clinically, higher LINC00578 expression was significantly associated with lymph node metastasis (P = 0.024), and TNM stage (P = 0.047) (Table S2). Furthermore, multivariate Cox regression analysis identified LINC00578 (P = 0.027, HR = 2.592, 95% confidence interval (CI) = 1.112-6.041), lymph node metastasis (P = 0.037, HR = 2.303, 95% CI = 1.051-5.049), and TNM stage (P = 0.041, hazard ratio = 2.463, 95% CI = 1.039-5.840) as independent prognostic factors (Table S3).

Figure 1.

LINC00578 was upregulated in LUAD and associated with poor prognosis. (a) LINC00578 expression levels in normal lung tissues (n = 59) and primary LUAD tumors (n = 533) from the TCGA-LUAD cohort (data sourced from UALCAN database: https://ualcan.path.uab.edu/cgi-bin/TCGA-lncRNA-Result.pl?genenam = LINC00578&ctype = LUAD. Statistical significance was analyzed by unpaired Student's t-test, P = 3.94 × 10⁻²³. (b) Relative expression of LINC00578 in 97 paired LUAD tissues and adjacent normal tissues. Data are presented as individual data points with mean ± SD. ***P < 0.001, paired Student's t-test. (c) Kaplan-Meier overall survival curves of LUAD patients stratified by low (n = 46) and high (n = 51) LINC00578 expression based on the mean expression value. P-value was determined by the log-rank test.

Regulatory relationship between LINC00578 and miR-153-5p

Conversely, miR-153-5p expression showed substantial downregulation in malignant specimens (P < 0.001; Figure 2(a)). A strong inverse correlation was observed between elevated LINC00578 and suppressed miR-153-5p levels in tumor tissues (r = -0.641, P < 0.001; Figure 2(b)). Consistent with the expression patterns observed in tissue samples, LINC00578 levels were significantly elevated in LUAD cell lines compared to normal control cells, while miR-153-5p expression was notably decreased (P < 0.001; Figure 3(a) and (b)). To further explore their interaction, functional assays were performed in PC-9 and H1299 cells, which were responsive to alterations in LINC00578 and miR-153-5p expression. To further verify the specific interaction between LINC00578 and miR-153-5p, dual-luciferase reporter assays were performed in PC-9 and H1299 cells. As shown in Figure 4(a) (PC-9) and 4B (H1299), overexpression of miR-153-5p (miR-mimic group) significantly reduced the relative luciferase activity of WT-LINC00578 compared to the miR-NC group (P < 0.001). Conversely, inhibition of miR-153-5p (miR-inhibitor group) markedly increased the luciferase activity of WT-LINC00578 (P < 0.001 vs. miR-NC group), which is attributed to the blockage of endogenous miR-153-5p that inherently suppresses LINC00578. Notably, for the MT-LINC00578 reporter (binding site seed region mutated), neither miR-153-5p mimic nor inhibitor had a significant effect on luciferase activity (all P > 0.05 vs. corresponding MT + miR-NC group; Figure 4(a) and (b)). This result confirms that the regulatory effect of miR-153-5p on LINC00578 is strictly dependent on the wild-type binding site—mutating the seed region abrogates the interaction between miR-153-5p and LINC00578, thus eliminating the regulatory effect. Silencing of LINC00578 with specific siRNA (si-LINC00578) effectively decreased its expression levels in both PC-9 and H1299 cells, whereas co-transfection with the miR-153-5p inhibitor did not affect LINC00578 expression, confirming the specific knockdown efficiency (P < 0.001, Figure 4(c)). Concurrently, knockdown of LINC00578 significantly upregulated miR-153-5p expression. This upregulation was effectively reversed by co-transfection with the miR-153-5p inhibitor, which alone successfully suppressed miR-153-5p levels (P < 0.001, Figure 4(d)). To directly visualize the functional outcome of this reciprocal regulation, we calculated the miR-153-5p/LINC00578 expression ratio. Silencing LINC00578 led to a dramatic increase in this ratio in both PC-9 and H1299 cells, which was significantly attenuated by miR-153-5p inhibition (P < 0.001, Figure 4(e) and (f), demonstrating that LINC00578 exerts its effect by modulating the abundance of miR-153-5p.

Figure 2.

miR-153-5p was downregulated in LUAD and inversely correlated with LINC00578 expression. (a) Relative expression levels of miR-153-5p in 97 paired LUAD tissues and adjacent normal tissues. Data are presented as individual data points with mean ± SD. ***P < 0.001 by paired Student's t-test. (b) Pearson correlation analysis showing a significant negative correlation between LINC00578 and miR-153-5p expression levels in LUAD tissues (n = 97, r = -0.641, P < 0.001).

Figure 3.

Expression patterns of LINC00578 and miR-153-5p in LUAD cell lines. (a) Relative expression of LINC00578 in normal human bronchial epithelial (HBE) cells and four LUAD cell lines (A549, H1299, PC-9, H2009). (b) Relative expression of miR-153-5p in the same panel of cells as in (a). Data in (a) and (b) are from five independent experiments (n = 5) and presented as mean ± SD. ***P < 0.001 versus HBE cells by one-way ANOVA with Tukey's post-hoc test.

Figure 4.

MiR-153-5p directly binds to and regulates LINC00578 in LUAD cells. (a) and (b) Dual-luciferase reporter assay in PC-9 (a) and H1299 (b) cells. Cells were co-transfected with either the wild-type (WT) or mutant (MT) LINC00578 reporter plasmid, along with the miR-153-5p mimic, miR-153-5p inhibitor (antagomir), or their negative controls (miR-NC). The pGL3-Control group represents cells transfected with the empty pGL3-basic vector to establish baseline activity. Firefly luciferase activity was normalized to Renilla luciferase activity. (c) Relative expression of LINC00578 in PC-9 and H1299 cells transfected with si-NC, si-LINC00578, or si-LINC00578 + miR-153-5p inhibitor. (d) Relative expression of miR-153-5p in the same groups as (c). (e) and (f) The miR-153-5p/LINC00578 expression ratio in PC-9 (e) and H1299 (f) cells. CK: Blank Control. Data are presented as mean ± SD (n = 5). ***P < 0.001 vs. miR-NC or si-NC; ##P < 0.001 vs. si + miR-NC; ns: not significant (P < 0.05) (one-way ANOVA with Tukey's post-hoc test).

Effects of LINC00578 and miR-153-5p on LUAD cell

In PC-9 and H1299 cells, LINC00578 knockdown significantly suppressed cell proliferation compared to controls (P < 0.001). However, co-inhibition of miR-153-5p markedly attenuated the inhibitory effect of LINC00578 silencing (P < 0.001, Figure 5(a) and (b)). Additionally, LINC00578 depletion reduced cell migration (Figure 5(c)) and invasion (Figure 5(d)) capacities and enhanced apoptosis (Figure 5(e)) in both cell lines. These effects were reversed upon miR-153-5p downregulation, suggesting a regulatory interplay between LINC00578 and miR-153-5p (P < 0.001).

Figure 5.

LINC00578 promotes malignant phenotypes in LUAD cells by sponging miR-153-5p. (a) and (b) Cell proliferation assessed by CCK-8 assay in PC-9 (a) and H1299 (b) cells transfected as indicated. Absorbance was measured at 450 nm. (c, d) Cell migration (c) and invasion (d) abilities assessed by Transwell assays in PC-9 and H1299 cells under the indicated treatments. (e) Flow cytometry analysis of apoptosis in PC-9 and H1299 cells under the indicated treatments. Data are mean ± SD (n = 5). ***P < 0.001 vs. si-NC group; ##P < 0.001 vs. si + miR-NC group (one-way ANOVA with Tukey's test).

Discussion

In recent years, LUAD's incidence and mortality rates have been rising globally due to the combined effects of environmental factors, genetic predispositions, and adverse lifestyle habits.²⁴ LUAD is characterized by high malignancy, rapid growth, and strong invasive potential into surrounding tissues and organs, complicating treatment strategies. In our study, we found that elevated LINC00578 expression might predict poor prognosis and malignant progression in LUAD patients, with miR-153-5p mediating the oncogenic effects of LINC00578 on LUAD cells.

Our study comprised 97 histologically confirmed LUAD cases, with comparative analysis revealing significantly elevated LINC00578 expression in tumor tissues relative to paired normal adjacent tissue samples. This observation aligns with existing literature documenting LINC00578 overexpression in LUAD pathogenesis, reinforcing its potential role as a consistent molecular marker in this malignancy.¹³ However, studies investigating the role of LINC00578 in cancer development are still relatively limited. As a differentially expressed, subtype-specific lncRNA in breast cancer, LINC00578 is implicated in tumor progression through pathways such as NOTCH/NF-κB signaling.²⁵ These findings suggest LINC00578 may as a promoter of tumorigenesis. Moreover, LINC00578 expression levels are significantly associated with T stage and patient mortality status in HCC,¹⁶ highlighting its potential as a prognostic biomarker. However, the apparent differences in the role of LINC00578 across different cancer types emphasize the complex, context-dependent nature of its function. Building on previous studies emphasizing the oncogenic role of LINC00578 in various malignancies, we further investigated its association with the clinicopathological features of LUAD. Our analysis identified LINC00578 expression, along with TNM stage and lymph node metastasis, as independent prognostic indicators. Additionally, previous studies have demonstrated that LINC00578 may modulate pro-tumorigenic polarization of M2 macrophages through regulation of Notch, transforming growth factor-beta (TGF-β), and interferon-α/γ response pathways, further underlining its involvement in lung cancer prognosis prediction models.²⁶

Prior research has reported that LINC00578 participates in several cellular processes relevant to disease progression. Li et al. reported that LINC00578 enhances proliferation and tumorigenicity of pancreatic cancer cells by stabilizing SLC7A11 protein expression through the UBE2 K/SLC7A11 axis, thereby inhibiting ferroptosis and promoting cancer progression.²⁷ Conversely, our findings suggest that silencing LINC00578 affects LUAD cell apoptosis, invasion, and proliferation in an opposing manner. Specifically, knockdown of LINC00578 suppressed LUAD cell invasiveness while markedly promoting apoptosis, providing further evidence that LINC00578 may function through inhibiting apoptotic pathways. Mechanistically, miR-153-5p was identified as a downstream competing endogenous RNA (ceRNA) of LINC00578. Importantly, our results demonstrate that miR-153-5p could counteract the oncogenic effects of LINC00578 in LUAD cells. For instance, in colorectal cancer, miR-153-5p acts as a tumor suppressor by inhibiting MYO6, with its function being compromised by circ_0000395-mediated sponging.²⁸ Therefore, we propose that the tumor-promoting role of LINC00578 in LUAD is at least partially mediated by miR-153-5p suppression.

In addition to identifying potential novel biomarkers for LUAD, our study highlights the significant advantages of using lncRNAs for monitoring tumor progression. First, we confirmed the prognostic significance of LINC00578 and elucidated its potential molecular mechanisms, underscoring the critical role of lncRNAs in cancer biology. Furthermore, by evaluating the expression of LINC00578 and miR-153-5p not only in tissue samples and cell lines using qRT-PCR but also in plasma specimens from LUAD patients, we expanded the potential application of these molecules as circulating biomarkers for disease diagnosis and prognosis.

Several study limitations warrant consideration. First, the restricted cohort size may limit the statistical power and broader applicability of our clinical findings. Although we validated LINC00578's upregulation using the TCGA dataset, the prognostic value of the LINC00578/miR-153-5p axis, particularly the clinical relevance of miR-153-5p itself, was not independently validated in a larger, multi-center population. Second, while our loss-of-function experiments robustly demonstrated the oncogenic role of LINC00578, the study lacked gain-of-function validation through LINC00578 overexpression, which would have provided complementary evidence for its oncogenic function. Third, our findings are primarily based on in vitro models. Validation through in vivo animal models is essential to confirm the functional roles of LINC00578 and miR-153-5p within a complex tumor microenvironment. Finally, the origin and transport mechanisms of these molecules, such as their presence in extracellular vesicles or exosomes, remain unexplored and could have significant biological implications.^29,30 Future research should address these limitations. Efforts will focus on validating the prognostic signature in larger, multi-center cohorts to assess its clinical utility. Gain-of-function studies with LINC00578 overexpression will be performed to further solidify its oncogenic role. Moreover, extensive in vivo experiments are planned to corroborate the tumor-promoting functions of the LINC00578/miR-153-5p axis and to explore its potential as a therapeutic target. Investigating the extracellular vesicle packaging and cell–cell communication mediated by this axis will also be a key direction to understand its broader role in LUAD progression.

In conclusion, elevated expression of LINC00578 in LUAD serves as an independent prognostic marker and is closely associated with disease progression. Mechanistically, LINC00578 promotes LUAD cell proliferation and metastasis, at least in part, through inhibition of miR-153-5p expression.

Supplemental Material

sj-docx-1-jbm-10.1177_03936155261417698 - Supplemental material for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p

Supplemental material, sj-docx-1-jbm-10.1177_03936155261417698 for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p by Wenju Pan, Jun Hong, Mingwei Zhang, Sumeng Wang, Xin Lu, Tingting Ji, Jing Zhang and Yaoman Guo in The International Journal of Biological Markers

Supplemental Material

sj-docx-2-jbm-10.1177_03936155261417698 - Supplemental material for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p

Supplemental material, sj-docx-2-jbm-10.1177_03936155261417698 for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p by Wenju Pan, Jun Hong, Mingwei Zhang, Sumeng Wang, Xin Lu, Tingting Ji, Jing Zhang and Yaoman Guo in The International Journal of Biological Markers

Supplemental Material

sj-docx-3-jbm-10.1177_03936155261417698 - Supplemental material for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p

Supplemental material, sj-docx-3-jbm-10.1177_03936155261417698 for LINC00578 as a prognostic biomarker in lung adenocarcinoma via regulation of miR-153-5p by Wenju Pan, Jun Hong, Mingwei Zhang, Sumeng Wang, Xin Lu, Tingting Ji, Jing Zhang and Yaoman Guo in The International Journal of Biological Markers

Footnotes

ORCID iD

Yaoman Guo

Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Jinling Hospital, The Affiliated Hospital of Medical School, Nanjing University. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Consent to publish

All patients provided written informed consent.

Author contributions

Wenju Pan, Xin Lu, Tingting Ji, Jing Zhang contributed to the study conception and design. Material preparation, data collection and analysis were performed by Wenju Pan, Jun Hong, Sumeng Wang, Yaoman Guo and Mingwei Zhang. The first draft of the manuscript was written by Wenju Pan and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability

All data generated or analyzed during this study are included in this article and its supplementary material files. Further enquiries can be directed to the corresponding author.

Supplemental material

Supplemental material for this article is available online.

References

Siegel

Miller

Wagle

, et al. Cancer statistics. CA Cancer J Clin 2023; 2023; 73.

Sung

Ferlay

Siegel

, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.

Kryczka

Migdalska-Sęk

Kordiak

, et al. Serum extracellular vesicle-derived miRNAs in patients with non-small cell lung cancer-search for non-invasive diagnostic biomarkers. Diagnostics (Basel) 2021; 11: 425.

Osmani

Askin

Gabrielson

, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 2018; 52: 103–109.

Jia

Zhang

, et al. Prognosis of early-stage lung adenocarcinoma in young patients. Clin Exp Pharmacol Physiol 2023; 50: 826–832.

Chen

Teng

Zhang

, et al. Molecular features of lung adenocarcinoma in young patients. BMC Cancer 2019; 19: 777.

Denisenko

Budkevich

Zhivotovsky

. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 2018; 9: 117.

Rayêe

Meier

Eliscovich

, et al. Nucleolar ribosomal RNA synthesis continues in differentiating lens fiber cells until abrupt nuclear degradation required for ocular lens transparency. RNA Biol 2025; 22: 1–16.

Wang

Guo

, et al. The long noncoding RNA CCDC144NL-AS1: prognosis significance and potential biological functions in cervical carcinoma. J Obstet Gynaecol 2025; 45: 2463416.

10.

Zhu

Shan

, et al. LncRNA CYTOR promotes pancreatic cancer cell proliferation and migration by sponging miR-205-5p. Pancreatology 2020; 20: 1139–1148.

11.

Wang

Xue

, et al. lncRNA-CYTOR works as an oncogene through the CYTOR/miR-3679-5p/MACC1 axis in colorectal cancer. DNA Cell Biol 2019; 38: 572–582.

12.

Liu

, et al. lncRNA cytoskeleton regulator RNA (CYTOR): diverse functions in metabolism, inflammation and tumorigenesis, and potential applications in precision oncology. Genes Dis 2023; 10: 415–429.

13.

Zhao

, et al. Expression profiles of long noncoding RNAs in lung adenocarcinoma. Onco Targets Ther 2018; 11: 5383–5390.

14.

Zhang

Sun

. Long non-coding RNA LINC00346, LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer. Am J Transl Res 2018; 10: 2648–2658.

15.

Jin

. A novel autophagy-related lncRNA prognostic risk model for breast cancer. J Cell Mol Med 2021; 25: 4–14.

16.

Liu

, et al. A nomogram based on 4-lncRNAs signature for improving prognostic prediction of hepatocellular carcinoma. Clin Transl Oncol 2024; 26: 375–388.

17.

Zhang

Tan

, et al. MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway. Biosci Biotechnol Biochem 2020; 84: 1645–1651.

18.

Wang

Zhang

, et al. MiR-153-5p enhances the sensitivity of triple-negative breast cancer cells to paclitaxel by inducing G2 M phase arrest. Onco Targets Ther 2020; 13: 4089–4097.

19.

Fang

Gao

, et al. LINC01354 Enhances the metastatic ability of gastric cancer cells by adjusting miR-153-5p/CADM2 expression. Am J Cancer Res 2023; 13: 2630–2643.

20.

Zhang

Liu

Pei

, et al. Long noncoding RNA HIF1A-AS2 promotes non-small cell lung cancer progression by the miR-153-5p/S100A14 axis. Onco Targets Ther 2020; 13: 8715–8722.

21.

Deng

Xue

Patel

, et al. Serum extracellular nano-vesicles miR-153-3p to identify micronodular lung cancer from sub-centimeter lung nodules. J Biomed Nanotechnol 2022; 18: 705–717.

22.

Rami-Porta

Asamura

Travis

, et al. Lung cancer - major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 138–155.

23.

Zhang

, et al. The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma. Open Med (Wars) 2023; 18: 20230686.

24.

Hutchinson

Shroff

Truong

, et al. Spectrum of lung adenocarcinoma. Semin Ultrasound CT MR 2019; 40: 255–264.

25.

Aktan

Küçükaslan

Türk

, et al. Expression analysis of novel long non-coding RNAs for invasive ductal and invasive lobular breast carcinoma cases. Pathol Res Pract 2023; 244: 154391.

26.

Fang

Yao

. Exploration of the long noncoding RNAs involved in the crosstalk between M2 macrophages and tumor metabolism in lung cancer. Genet Res (Camb) 2023; 2023: 4512820.

27.

Wei

Wang

, et al. Long noncoding RNA LINC00578 inhibits ferroptosis in pancreatic cancer via regulating SLC7A11 ubiquitination. Oxid Med Cell Longev 2023; 2023: 1744102.

28.

Xiao

Zhu

, et al. Circ_0000395 promotes cell growth, metastasis and oxaliplatin resistance by regulating miR-153-5p/MYO6 in colorectal cancer. Pathol Res Pract 2024; 260: 155476.

29.

Zheng

Wen

Jiang

, et al. CircRNA/lncRNA-miRNA-mRNA network and gene landscape in calcific aortic valve disease. BMC Genomics 2023; 24: 419.

30.

Wen

Ruan

Wang

, et al. Construction of atrial fibrillation-related circRNA/lncRNA-miRNA-mRNA regulatory network and analysis of potential biomarkers. J Clin Lab Anal 2023; 37: e24833.